Recent advances in neurokinin-3 receptor antagonists

Autor:	Mario Grugni, Luca F. Raveglia, Giuseppe Am Giardina
Rok vydání:	2000
Předmět:	Pharmacology business.industry Inflammation General Medicine Disease Inflammatory pain chemistry.chemical_compound chemistry Drug Discovery Medicine Biological evidence medicine.symptom Neurokinin B business Receptor Neurokinin 3 receptor
Zdroj:	Expert Opinion on Therapeutic Patents. 10:939-960
ISSN:	1744-7674 1354-3776
DOI:	10.1517/13543776.10.6.939
Popis:	This review addresses the recent highlights and progress made in the neurokinin-3 (NK-3) receptor area since the last update, provided in this journal in 1997. Whereas in the neurokinin-1 (NK-1) and neurokinin-2 (NK-2) biological areas literature information based on clinical data account for a high therapeutic potential (in emesis and depression for NK-1 and asthma for NK-2 receptor antagonists), there is a total deficiency of information from NK-3 receptor antagonists in clinical development. No other chemical classes in addition to dichlorophenylalkylpiperidines, represented by SR 142,801 and quinolines, represented by SB-222200 and SB-223412, have been identified by pharmaceutical companies and scientists involved in the specific field. Biological evidence indicates pain/inflammation as a suitable CNS-related therapeutic target, this conclusion is based on localisation studies and efficacy of selected NK-3 receptor antagonists in rat disease models of inflammatory pain. In the periphery, the most like...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::19bf8d341c380d1a484312c8e7d82342 https://doi.org/10.1517/13543776.10.6.939 Zobrazit plný text záznamu